Acquired Company

AbbVie acquired ImmunoGen on 2/12/2024 for $31.26 per share in cash, representing a total transaction value of about $10.1 billion.

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days. Show more

84 State St, Massachusetts, 02109-2202, US

www.immunogen.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$31.23

Open

$31.23

Volume

N/A

Day Range

$31.23 - $31.23

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.32%

Institutional Own.

86.52%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Mirvetuximab Soravtansine (Folate receptor alpha (FRa)) Details Ovarian cancer, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELAHERE (Mirvetuximab Soravtansine) Details Cancer, Ovarian cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pivekimab Sunirine (IMGN632) (Anti-CD123 ADC) + Venclexta® + Vidaza® Details Cancer, Acute myeloid leukemia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pivekimab Sunirine (IMGN632) (Anti-CD123 ADC) Details Blastic plasmacytoid dendritic cell neoplasm	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mirvetuximab Soravtansine (Folate receptor alpha (FRa)) Details Ovarian cancer, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMGC936 Details Solid tumor/s, Cancer, Triple-negative breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMGN151 (anti-ADAM9 ADC) Details Cancer, Solid tumor/s, Endometrial cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.